Legend Biotech's (LEGN) current valuations provide "a buying opportunity," according to analysts at RBC Capital Markets, who said in a note to clients Thursday that the biopharmaceutical company has resolved concerns about its accounting standards and SEC compliance.
The analysts also said Legend's Carvykti is a "best-in-class option" to treat multiple myeloma. "We believe this will continue to drive both patient and physician demand," the analysts wrote. "We see the strength of the data likely supporting successful expansion into earlier lines."
The analysts also said they believe Carvykti has a lot of upside, noting that one-third of doctors haven't heard of the drug.
RBC has an outperform rating on the stock with a $78 price target.
Shares of Legend Biotech were down 1.9% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.